Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982;14(Suppl 2):179S–186S. doi: 10.1111/j.1365-2125.1982.tb02075.x

Regional circulatory response to converting-enzyme inhibition in congestive heart failure

D P Faxon, M A Creager, J L Halperin
PMCID: PMC1427528  PMID: 6753899

Abstract

1 To determine the distribution of flow, the regional haemodynamic response to 100 mg of captopril was determined in 36 patients with refractory cardiac heart failure. Measurements included forearm blood flow by venous occlusion plethysmography (eight patients), splanchnic blood flow by indocyanine green clearance (10 patients), and coronary blood flow by thermodilution (12 patients).

2 Cardiac index significantly rose in one hour (1.9 ± 0.1 to 2.2 ± 0.1 l/m/m2, p < 0.01) while forearm blood flow rose slightly (2.9 ± 0.8 to 3.2 ± 0.3 ml/100 ml/min). Renal blood flow rose significantly by 30% (344 ± 48 to 533 ± 82 ml/min, p < 0.02). Despite a fall in rate pressure product (8.8 ± 0.7 to 7.1 ± 0.5 mm Hg bt × 103, p < 0.02), coronary blood flow did not significantly change (160 ± 20 to 133 ± 12 ml/min), indicating an improved supply-demand relationship.

3 External myocardial efficiency improved (19 ± 3 to 26 ± 6%, p < 0.05). Coronary blood flow is unaffected and converting-enzyme inhibitor improves myocardial efficiency. This strategic reduction in vascular impedence distinguishes converting-enzyme inhibitors as a unique class of vasodilators in the treatment of coronary heart failure.

Full text

PDF
180S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderman E. L., Glantz S. A. Acute hemodynamic interventions shift the diastolic pressure-volume curve in man. Circulation. 1976 Oct;54(4):662–671. doi: 10.1161/01.cir.54.4.662. [DOI] [PubMed] [Google Scholar]
  2. Awan N. A., Miller R. R., Miller M. P., Specht K., Vera Z., Mason D. T. Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output. Am J Med. 1978 Jul;65(1):146–154. doi: 10.1016/0002-9343(78)90703-9. [DOI] [PubMed] [Google Scholar]
  3. Ben-Jonathan N., Porter J. C. A sensitive radioenzymatic assay for dopamine, norepinephrine, and epinephrine in plasma and tissue. Endocrinology. 1976 Jun;98(6):1497–1507. doi: 10.1210/endo-98-6-1497. [DOI] [PubMed] [Google Scholar]
  4. Brenner B. M., Schor N., Ichikawa I. Role of angiotensin II in the physiologic regulation of glomerular filtration. Am J Cardiol. 1982 Apr 21;49(6):1430–1433. doi: 10.1016/0002-9149(82)90356-3. [DOI] [PubMed] [Google Scholar]
  5. Cogan J. J., Humphreys M. H., Carlson C. J., Rapaport E. Renal effects of nitroprusside and hydralazine in patients with congestive heart failure. Circulation. 1980 Feb;61(2):316–323. doi: 10.1161/01.cir.61.2.316. [DOI] [PubMed] [Google Scholar]
  6. Creager M. A., Halperin J. L., Bernard D. B., Faxon D. P., Melidossian C. D., Gavras H., Ryan T. J. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation. 1981 Sep;64(3):483–489. doi: 10.1161/01.cir.64.3.483. [DOI] [PubMed] [Google Scholar]
  7. Curtiss C., Cohn J. N., Vrobel T., Franciosa J. A. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978 Nov;58(5):763–770. doi: 10.1161/01.cir.58.5.763. [DOI] [PubMed] [Google Scholar]
  8. Davis R., Ribner H. S., Keung E., Sonnenblick E. H., LeJemtel T. H. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med. 1979 Jul 19;301(3):117–121. doi: 10.1056/NEJM197907193010301. [DOI] [PubMed] [Google Scholar]
  9. Dzau V. J., Colucci W. S., Williams G. H., Curfman G., Meggs L., Hollenberg N. K. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med. 1980 Jun 19;302(25):1373–1379. doi: 10.1056/NEJM198006193022501. [DOI] [PubMed] [Google Scholar]
  10. Faxon D. P., Creager M. A., Halperin J. L., Gavras H., Coffman J. D., Ryan T. J. Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure. Circulation. 1980 May;61(5):925–930. doi: 10.1161/01.cir.61.5.925. [DOI] [PubMed] [Google Scholar]
  11. Faxon D. P., Halperin J. L., Creager M. A., Gavras H., Schick E. C., Ryan T. J. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J. 1981 May;101(5):548–556. doi: 10.1016/0002-8703(81)90220-9. [DOI] [PubMed] [Google Scholar]
  12. GORDY E., DRABKIN D. L. Spectrophotometric studies. XVI. Determination of the oxygen saturation of blood by a simplified technique, applicable to standard equipment. J Biol Chem. 1957 Jul;227(1):285–299. [PubMed] [Google Scholar]
  13. Ganz W., Tamura K., Marcus H. S., Donoso R., Yoshida S., Swan H. J. Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation. 1971 Aug;44(2):181–195. doi: 10.1161/01.cir.44.2.181. [DOI] [PubMed] [Google Scholar]
  14. Gavras H., Faxon D. P., Berkoben J., Brunner H. R., Ryan T. J. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation. 1978 Nov;58(5):770–776. doi: 10.1161/01.cir.58.5.770. [DOI] [PubMed] [Google Scholar]
  15. Hollenberg N. K., Williams G. H., Taub K. J., Ishikawa I., Brown C., Adams D. F. Renal vascular response to interruption of the renin-angiotensin system in normal man. Kidney Int. 1977 Oct;12(4):285–293. doi: 10.1038/ki.1977.113. [DOI] [PubMed] [Google Scholar]
  16. Johnston C. I., Clappison B. H., Anderson W. P., Yasujima M. Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol. 1982 Apr 21;49(6):1401–1404. doi: 10.1016/0002-9149(82)90350-2. [DOI] [PubMed] [Google Scholar]
  17. Klocke F. J., Ellis A. K. Control of coronary blood flow. Annu Rev Med. 1980;31:489–508. doi: 10.1146/annurev.me.31.020180.002421. [DOI] [PubMed] [Google Scholar]
  18. Mann T., Cohn P. F., Holman L. B., Green L. H., Markis J. E., Phillips D. A. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation. 1978 Apr;57(4):732–738. doi: 10.1161/01.cir.57.4.732. [DOI] [PubMed] [Google Scholar]
  19. Miller R. R., Vismara L. A., Williams D. O., Amsterdam E. A., Mason D. T. Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Differential effects of nitroprusside, phentolamine, and nitroglycerin on cardiac function and peripheral circulation. Circ Res. 1976 Jul;39(1):127–133. doi: 10.1161/01.res.39.1.127. [DOI] [PubMed] [Google Scholar]
  20. Sealey J. E., Gerten-Banes J., Laragh J. H. The renin system: Variations in man measured by radioimmunoassay or bioassay. Kidney Int. 1972 Apr;1(4):240–253. doi: 10.1038/ki.1972.34. [DOI] [PubMed] [Google Scholar]
  21. Smith H. W., Finkelstein N., Aliminosa L., Crawford B., Graber M. THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN. J Clin Invest. 1945 May;24(3):388–404. doi: 10.1172/JCI101618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. St Cyr M. J., Sancho J. M., Melby J. C. Quantitation of plasma aldosterone by radioimmunoassay. Clin Chem. 1972 Nov;18(11):1395–1402. [PubMed] [Google Scholar]
  23. WIEGAND B. D., KETTERER S. G., RAPAPORT E. The use of indocyanine green for the evaluation of hepatic function and blood flow in man. Am J Dig Dis. 1960 May;5:427–436. doi: 10.1007/BF02232628. [DOI] [PubMed] [Google Scholar]
  24. WOOD J. E. Peripheral venous and arteriolar responses to infusions of angiotensin in normal and hypertensive subjects. Circ Res. 1961 May;9:768–774. doi: 10.1161/01.res.9.3.768. [DOI] [PubMed] [Google Scholar]
  25. Zelis R., Flaim S. F., Moskowitz R. M., Nellis S. H. How much can we expect from vasodilator therapy in congestive heart failure? Circulation. 1979 Jun;59(6):1092–1097. doi: 10.1161/01.cir.59.6.1092. [DOI] [PubMed] [Google Scholar]
  26. Zelis R., Longhurst J., Capone R. J., Mason D. T. A comparison of regional blood flow and oxygen utilization during dynamic forearm exercise in normal subjects and patients with congestive heart failure. Circulation. 1974 Jul;50(1):137–143. doi: 10.1161/01.cir.50.1.137. [DOI] [PubMed] [Google Scholar]
  27. Zelis R., Mason D. T. Compensatory mechanisms in congestive heart failure--the role of the peripheral resistance vessels. N Engl J Med. 1970 Apr 23;282(17):962–964. doi: 10.1056/NEJM197004232821707. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES